# Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

> **NCT00394992** · PHASE3 · TERMINATED · sponsor: **Dutch Colorectal Cancer Group** · enrollment: 79 (actual)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** oxaliplatin+capecitabine
- **DRUG:** Oxaliplatin+capecitabine+bevacizumab

## Key facts

- **NCT ID:** NCT00394992
- **Lead sponsor:** Dutch Colorectal Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Data from the C08 study and Avant study
- **Last updated:** 2014-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394992, "Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00394992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*